Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

New Upgrade:   Dedicated Screeners for Stocks & ETFs

Learn more
Market News Market Pulse Stocks News ETF News Crypto News

Tango Therapeutics, Inc.

Contributing Author

Recent Articles by Tango Therapeutics, Inc.

Oct-23
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy TNGX -16.43% GlobeNewswire
Oct-16
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 TNGX GlobeNewswire
Sep-03
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TNGX GlobeNewswire
Sep-01
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference TNGX GlobeNewswire
Aug-11
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights TNGX GlobeNewswire
Aug-06
Tango Therapeutics Announces Executive Chair Transition TNGX TNGX -6.66% GlobeNewswire
Aug-06
Tango Therapeutics Announces Executive Chair Transition TNGX TNGX -6.66% GlobeNewswire
Jun-22
Tango Therapeutics Appoints Robert Azelby to Board of Directors TNGX GlobeNewswire
Jun-09
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering TNGX -9.13% GlobeNewswire
Jun-08
Tango Therapeutics Announces Proposed $500 Million Public Offering TNGX +52.97% GlobeNewswire
Jun-08
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer TNGX +52.97% GlobeNewswire
Jun-05
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TNGX -8.71% GlobeNewswire
May-13
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights TNGX +8.55% GlobeNewswire
Oct-06
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 TNGX GlobeNewswire
Aug-26
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference TNGX GlobeNewswire
Aug-05
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights TNGX GlobeNewswire
Jul-22
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 TNGX GlobeNewswire
Jun-27
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer TNGX GlobeNewswire
May-27
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference TNGX +11.41% GlobeNewswire
May-21
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors TNGX -8.70% GlobeNewswire
May-12
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights TNGX +14.91% GlobeNewswire
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)